Drug intelligence / Profile preview

cisplatin + fluorouracil + pegylated liposomal doxorubicin

Development stage: Unknown
Lead developer: Michigan State University
Modality: Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of cisplatin, fluorouracil (5-FU), and pegylated liposomal doxorubicin. The pegylated liposomal formulation of doxorubicin encapsulates the drug in polyethylene glycol (PEG) coated liposomes, which protects it from detection by the immune system and extends its circulation time. This formulation allows for preferential accumulation in tumor tissues due to their leaky vasculature while reducing exposure to normal tissues. When combined with cisplatin and fluorouracil, this regimen provides a multi-targeted approach to cancer treatment.

Targets

TOP2A (DNA topoisomerase II)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on cisplatin + fluorouracil + pegylated liposomal doxorubicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + fluorouracil + pegylated liposomal doxorubicin.

Explore the full profile